India, Feb. 27 -- Neurocrine Biosciences Inc. (NBIX) announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained effects of INGREZZA (valbenazine) capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia, irrespective of tardive dyskinesia severity or underlying psychiatric condition.
The company noted that the KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically INGREZZA, on tardive dyskinesia or TD using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale used to evaluate the physical, social and emotional impact of involuntary movement...